|drug4022||prophylactic heparin Wiki||1.00|
|drug1974||Maximal effort test Wiki||1.00|
|drug2173||Neuromuscular evaluation Wiki||1.00|
|D015673||Fatigue Syndrome, Chronic NIH||1.00|
There is one clinical trial.
This is a randomized, open label, adaptive platform trial to compare the effectiveness of antithrombotic strategies for prevention of adverse outcomes in COVID-19 positive inpatients
Description: which is defined as the number of days that a patient is alive and free of organ support through the first 21 days after trial entry. Organ Support is defined as receipt of non-invasive mechanical ventilation, high flow nasal canula oxygen, mechanical ventilation, or vasopressor therapy, with death at any time during the index hospitalization assigned -1 days.Measure: 21 Day Organ Support (respiratory or vasopressor) Free Days Time: 21 days from study enrollment
Description: Composite endpoint of death, pulmonary embolism, systemic arterial thromboembolism, myocardial infarction, or ischemic stroke at hospital discharge or 28 days, whichever occurs firstMeasure: Key Platform Secondary Thrombotic Endpoint Time: 28 days from study enrollment
Description: Acute kidney injury defined by KDIGO criteria, Individual endpoints comprising the key secondary endpoint, death during hospitalization, 28 Day Ventilator-Free Days, 28 Day Vasopressor Free Days, 28 Day Renal Replacement Free Days, WHO clinical scale, 28 Day Hospital Free Days, 28 day organ support free days.Measure: Other Platform Secondary Endpoints of Morbidity and Hospitalization Time: 28 days from study enrollment
Description: Any mortality of patients enrolled within 90 days.Measure: All cause mortality Time: 90 days from enrollment
Description: Major bleeding (as defined by the ISTH)Measure: Primary Safety Endpoint of Major Bleeding Time: 28 days from study enrollment
Description: Confirmed heparin induced thrombocytopenia (HIT)Measure: Secondary Safety Endpoint of HIT Time: 28 days from study enrollment
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports